Lawsuits are being filed against Sanofi and Regeneron, the manufacturers of Dupixent (dupilumab), alleging that the drug causes or accelerates T-Cell Lymphoma, specifically Cutaneous T-Cell Lymphoma (CTCL). The first wrongful death lawsuit was filed in October 2025, involving a patient who died from T-cell lymphoma shortly after starting the treatment.
Plaintiffs claim that the manufacturers failed to warn doctors and patients about these risks despite growing evidence. Studies have shown a significant increase in lymphoma risk for Dupixent users, yet the drug's warning label does not currently include T-cell lymphoma as a potential side effect.
Dupixent (dupilumab) is an FDA-approved prescription biologic used to treat moderate-to-severe eczema (atopic dermatitis), asthma, and chronic rhinosinusitis with nasal polyps. It works by blocking IL-4 and IL-13 proteins to inflammation. However, by suppressing specific immune pathways, it may also suppress the body's natural defense against abnormal cell growth, potentially leading to cancer.
The primary concern in these lawsuits is the development of Cutaneous T-Cell Lymphoma (CTCL), a rare cancer of the immune system that manifests on the skin.
Warning Signs of CTCL
Skin Lesions: Red, scaly patches or thick plaques that may be mistaken for eczema.
Itching & Pain: Persistent discomfort in affected areas.
Swollen Lymph Nodes: A common sign of lymphoma.
Systemic Symptoms: Fatigue, weight loss, and night sweats.
Key Research Findings
Increased Risk: A 2024 study suggests a 300% to 350% higher risk of CTCL in Dupixent users.
Rapid Progression: Case reports describe patients whose cancer accelerated rapidly after starting the drug.
Misdiagnosis: Doctors may mistake early cancer signs for worsening eczema, delaying life-saving treatment.
If you developed T-Cell Lymphoma after taking Dupixent, you may be entitled to compensation for medical bills, lost wages, and pain and suffering.
You typically qualify if you:
Used Dupixent (dupilumab) as prescribed for conditions like eczema or asthma.
Were subsequently diagnosed with T-Cell Lymphoma or Cutaneous T-Cell Lymphoma (CTCL).
Suffered from worsening skin symptoms that were later confirmed to be cancer.
Are a family member of a patient who passed away from lymphoma linked to Dupixent use.
Lawsuits allege that Dupixent (dupilumab) makers, Sanofi and Regeneron, failed to warn patients and doctors that the drug could cause or accelerate T-cell lymphoma, particularly Cutaneous T-Cell Lymphoma (CTCL), or worsen existing hidden cancers.
Warning signs include red, scaly patches or thick plaques on the skin, itching or pain in affected areas, swollen lymph nodes, fatigue, and weight loss. In some cases, these symptoms may be mistaken for worsening eczema.
Yes. Several 2024 and 2025 studies have found a significant increase in CTCL risk among Dupixent users. A 2025 study led by Sheng-Kai Ma found a more than 4.5 times higher risk of CTCL in asthma patients using dupilumab compared to other treatments.
You may be eligible if you used Dupixent as prescribed and were subsequently diagnosed with T-Cell Lymphoma, especially CTCL. Surviving family members of patients who died from these conditions may also file a wrongful death claim.